Bernard Lipman

Array ( [id] => 17386065 [patent_doc_number] => 20220033917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => CANCER CELL METHYLATION MARKERS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/503666 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11892 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17503666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436511 [patent_doc_number] => 20230183805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => RESIDUAL ENZYME ACTIVITY IN METABOLIC DISEASE [patent_app_type] => utility [patent_app_number] => 17/607436 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607436 [rel_patent_id] =>[rel_patent_doc_number] =>)